BiTE therapy for rheumatoid arthritis

Frances Humby; Bruce Kirkham; Leonie Taams

doi:10.1038/s41591-024-02982-z

BiTE therapy for rheumatoid arthritis

Frances Humby^*, Bruce Kirkham, Leonie Taams

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.

Original language	English
Pages (from-to)	1533-1534
Number of pages	2
Journal	Nature Medicine
Volume	30
Issue number	6
DOIs	https://doi.org/10.1038/s41591-024-02982-z
Publication status	Published - Jun 2024

Access to Document

10.1038/s41591-024-02982-z

Cite this

@article{5560d9899167498598b505651941a2f6,

title = "BiTE therapy for rheumatoid arthritis",

abstract = "A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.",

author = "Frances Humby and Bruce Kirkham and Leonie Taams",

note = "Publisher Copyright: {\textcopyright} Springer Nature America, Inc. 2024.",

year = "2024",

month = jun,

doi = "10.1038/s41591-024-02982-z",

language = "English",

volume = "30",

pages = "1533--1534",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - BiTE therapy for rheumatoid arthritis

AU - Humby, Frances

AU - Kirkham, Bruce

AU - Taams, Leonie

N1 - Publisher Copyright: © Springer Nature America, Inc. 2024.

PY - 2024/6

Y1 - 2024/6

N2 - A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.

AB - A pilot study suggests that the bispecific T cell engager blinatumomab may provide a new therapy for patients with refractory rheumatoid arthritis; larger studies and deep phenotyping will be crucial to thoroughly evaluate and optimize this approach.

UR - http://www.scopus.com/inward/record.url?scp=85192699290&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-02982-z

DO - 10.1038/s41591-024-02982-z

M3 - Comment/debate

C2 - 38720000

AN - SCOPUS:85192699290

SN - 1078-8956

VL - 30

SP - 1533

EP - 1534

JO - Nature Medicine

JF - Nature Medicine

IS - 6

ER -

BiTE therapy for rheumatoid arthritis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this